May 18, 2020
Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations
May 13, 2020
Janssen's BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
Apr 23, 2020
Johnson & Johnson Announces Collaboration to Expand Manufacturing Capabilities For its COVID-19 Vaccine Candidate in Support of the Company's Goal to Supply More Than One Billion Vaccine Doses Globally
Apr 21, 2020
U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
Mar 18, 2020
Janssen Submits Ponesimod New Drug Application to the U.S. FDA for Treatment of Adults with Relapsing Multiple Sclerosis
Mar 02, 2020
European Medicines Agency Grants PRIME and Advanced Therapy Medicinal Product Designations to Janssen's RPGR Gene Therapy for X-Linked Retinitis Pigmentosa
Feb 25, 2020
Johnson & Johnson Launches Heartline(TM), the First-of-its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch Can Help Reduce the Risk of Stroke
Feb 14, 2020
New Phase 3b Interim Data from STARDUST Study Show Two-Thirds of Patients with Moderately to Severely Active Crohn's Disease Achieved Clinical Remission After Two Doses of STELARA® (ustekinumab)
Feb 10, 2020
Janssen Announces Submission to U.S. FDA for New DARZALEX® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma
Feb 04, 2020
Daily Disposable (DD) Lens Market Study, 2015-2025 - Includes Profiles of Johnson & Johnson, Cooper, Bausch Health, and Alcon
Dec 10, 2019
DARZALEX® (Daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Dec 08, 2019
Johnson & Johnson Announces Commitment to Support Republic of Rwanda's Preparedness Against Ebola Outbreak
Dec 07, 2019
Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma
Dec 07, 2019
Janssen to Acquire Investigational Bermekimab from XBiotech
Oct 21, 2019
Janssen Announces U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
Oct 17, 2019
Janssen Presents New Four-Year TREMFYA® (guselkumab) Data Demonstrating Maintained Rates of Skin Clearance in Adult Patients with Moderate to Severe Plaque Psoriasis
Oct 03, 2019
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Niraparib for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Oct 01, 2019
Johnson & Johnson Reaches Settlement Agreement with Two Ohio Counties Ahead of Upcoming Opioid Trial
Sep 18, 2019
Johnson & Johnson to Host Investor Conference Call on Third Quarter Results
Sep 18, 2019
Artist/Activist Domenic Esposito Places 800 lb Opioid Spoon Sculpture at Johnson & Johnson Headquarters to Shine a Light on Sinister Opioid Production and Distribution Practices